Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia

target: NF-κB; Ser/Thr Protease; Toll-like Receptor (TLR)

Research Areas: Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease; Cancer